SERN | Southeast NBS & Genetics Regional Collaborative

Like us on Facebook! Follow SERC_Genetics on Twitter Subscribe to our RSS Feed
Login | Contact Us

COVID-19 is an emerging, rapidly evolving situation.

Hans C. Andersson, MD

Hans C. Andersson, MD   

SERN Workgroups & Committees
Academic Contact
Biochem Lab
Diagnostic Lab Director
Medical Geneticist

Centers & Contact Information
Hans C. Andersson, MD is the Karen Gore Chair of Human Genetics and Director of the Hayward Genetics Center at the Tulane University Medical School where he directs the Biochemical Genetics Lab. Dr. Andersson is the past President of the SouthEast Regional Genetics Group (SERGG), holds membership of numerous national societies including the Society of Pediatric Research and is a member of the Editorial Board of the Journal of Pediatrics. He is past Co-Chair of the National Coordinating Center Telegenetics Workgroup and a current CO-PI of the Southeast Regional Genetics Network (SERN).

Selected Publications
Selected Publications by the Presenter
(from a total of 50 publications)

Andersson HC, Kratz L, Kelley RDesmosterolosis Presenting with Multiple Congenital Anomalies and Profound Developmental Delay. Am J     Med Genet 113:315-319, 2002.

Andersson  HC, MA Krousel-Wood, KE Jackson, J Rice, IM Lubin.Medical Genetic Test Reporting in Molecular Cystic Fibrosis and Factor V                Leiden Tests Based On Reports Solicited From North American Laboratories. Gen in Med 4(5):324-7 2002.

Andersson HC,  Charrow J, Kaplan P, Mistry P, Pastores G, Prakesh-Cheng A, Rosenbloom BE, Scott R, Wappner RS, Weinreb NJ.                              Individualization of Long-term Enzyme Replacement Therapy for Gaucher Disease. Genet in Med  Feb 7:105-110, 2005.

Andersson HC, Narumanchi TC, Cunningham A, Bowdish B, Thoene J. Genetic/Metabolic Health Care Delivery During and After Katrina and   Rita, Molecular Genetics and Metabolism, 88:3-6, 2006.

Andersson HC, Kaplan P, Kacena K, J Yee. Eight-year clinical outcomes of long-term enzyme replacement therapy in 884 children with type 1          Gaucher disease, Pediatrics 2008; 122;1182-1190.

Andersson HC, Kaplan P, Kacena K, J Yee. Eight-year clinical outcomes of long-term enzyme replacement therapy in 884 children with type 1 Gaucher disease, Pediatr,122:1182, 2008

Andersson, Perry W, Bowdish B, P Floyd-Browning. Emergency preparedness for genetics centers, laboratories and patients: the SouthEast Region Genetics Collaborative strategic plan. Genet Med, ePub: June, 2011, October, 2011.

SERN Highlights
July 2020

A Taste of eGNA: Now Expanding with Project ECHO

A Taste of eGNA: Now Expanding with Project ECHO

The Southeast Regional Genetics Network (SERN) is ready to launch its first Project ECHO platform for genetic disorders. Our first pilot project will focus on a multidisciplinary medical education approach focused on training genetic metabolic providers. We are currently recruiting for the Genetic Nutrition ECHO program which will launch in the fall of 2020. We hosted an ECHO methodology demonstration on Wednesday, April 29 where more than 300 genetic professionals, public health professionals, and other providers registered to learn more about Project ECHO. We had three case presenters from different institutions, active audience participation, and faculty experts who provided recommendations. If you are a genetic professional, currently seeing patients, we would like your help in completing the Genetic Nutrition ECHO Needs Assessment.

In addition, if you are interested in further educational opportunities, you will be directed to complete the Participant Interest Form after completing the needs assessment, which the ECHO team will use to enroll the first trainee cohort for the program and interested members will be provided with more details. For any further questions please contact

Home | About | Contact Us
This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $600,000.00 with 0 percent financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit